(VCBeat) Apr. 23, 2021 -- Shanghai Ruilong Nuofu Medical Technology Co., Ltd. ("Ronovo Surgical") announced that it has successfully completed a Series A financing of hundreds of millions. Ronovo Surgical is a medical company focusing on minimally invasive surgery (MIS) and digital surgery, committed to meeting the huge demand of the Chinese surgical market with innovative technologies.

Ronovo Surgical was founded in Shanghai in 2019, with a team of renowned roboticists and surgeons of MIS from home and abroad. Based on the national health and medical reform for the needs of the continuous improvement of clinical diagnosis and treatment, Ronovo Surgical is devoted to building an MIS and digital technology platform and ecosystem around the operating room based on self-research and global cooperation.

This round of financing is co-led by Matrix Partners China and Vivo Capital, with participation from GGV Capital and the seed round investor Lilly Asia Ventures.

Ronovo Surgical was founded in Shanghai in 2019 by industry experts from the global industry in surgery and industrial robotics, such as Zhiguan Medical, Johnson & Johnson, Medtronic, and Kuka. With strong research and development capabilities and global strategic collaboration, Ronovo Surgical accelerates the development and collaboration of MIS and digital surgery solutions and is determined to bring innovation to the traditional operating room with simplification, precision, and intelligence as the core.

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high-quality companies. Since its inception, the firm has raised over $5.8 billion in capital and backed over 300 private and public portfolio companies. Vivo Capital is headquartered in Palo Alto, California, with offices in Beijing, Shanghai, Hong Kong, and Taipei.

Vivo Capital is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.